Literature DB >> 1420037

The red eye of renal failure: a crystal induced inflammation?

N Klaassen-Broekema1, O P van Bijsterveld.   

Abstract

Of 57 patients with chronic renal failure and calcification of the anterior membranes of the eye eight developed inflammatory reactions, clinically indistinguishable from pingueculitis. In three patients an acute inflammatory reaction of the episcleral tissue and the conjunctiva over it developed which we considered to represent the red eye of renal failure. In these patients massive shedding of calcium phosphate salts was clinically evident. Histopathologically in all these patients calcific deposits were observed. Although sporadically polymorphonuclear leucocytes were present in the inflamed tissues we could not demonstrate crystal phagocytosis. We believe that in the red eyes in renal failure and, more specifically, in the red eyes of renal failure a crystal induced inflammatory mechanism is not operative.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1420037      PMCID: PMC505218          DOI: 10.1136/bjo.76.10.578

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  CRYSTAL DEPOSITION DISEASES: SODIUM URATE (GOUT) AND CALCIUM PYROPHOSPHATE (CHONDROCALCINOSIS, PSEUDOGOUT).

Authors:  D J MCCARTY; R A GATTER; J M BRILL; J M HOGAN
Journal:  JAMA       Date:  1965-07-12       Impact factor: 56.272

2.  Morphological study of articular cartilage in pyrophosphate arthropathy. (Chondrocalcinosis articularis or calcium pyrophosphate dihydrate crystal deposition diseases).

Authors:  A O Bjelle
Journal:  Ann Rheum Dis       Date:  1972-11       Impact factor: 19.103

3.  Red eyes in renal failure.

Authors:  G M Berlyne; A B Shaw
Journal:  Lancet       Date:  1967-01-07       Impact factor: 79.321

4.  The effect of synovial hyaluronate on the ingestion of monosodium urate crystals by leukocytes.

Authors:  K D Brandt
Journal:  Clin Chim Acta       Date:  1974-09-30       Impact factor: 3.786

5.  Unusual ocular calcification in hyperparathyroidism.

Authors:  J W Berkow; B S Fine; L E Zimmerman
Journal:  Am J Ophthalmol       Date:  1968-11       Impact factor: 5.258

6.  Adsorption of polymorphonuclear leukocyte lysosomal enzymes to monosodium urate crystals.

Authors:  M H Ginsberg; F Kozin; D Chow; J May; J L Skosey
Journal:  Arthritis Rheum       Date:  1977 Nov-Dec

7.  Recurrent acute inflammation associated with focal apatite crystal deposition.

Authors:  D J McCarty; R A Gatter
Journal:  Arthritis Rheum       Date:  1966-12

8.  Serum and plasma inhibit neutrophil stimulation by hydroxyapatite crystals. Evidence that serum alpha 2-HS glycoprotein is a potent and specific crystal-bound inhibitor.

Authors:  R A Terkeltaub; D A Santoro; G Mandel; N Mandel
Journal:  Arthritis Rheum       Date:  1988-09

9.  Red eyes in renal failure.

Authors:  N Klaassen-Broekema; O P van Bijsterveld
Journal:  Br J Ophthalmol       Date:  1992-05       Impact factor: 4.638

10.  Hydroxyapatite phagocytosis by human polymorphonuclear leucocytes.

Authors:  K H Maurer; H R Schumacher
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

View more
  3 in total

1.  Impression cytology of the conjunctival epithelium in patients with chronic renal failure.

Authors:  D Dursun; B Demirhan; S Oto; P Aydin
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Sociodemographic Factors and Comorbidities Including Hyperparathyroidism Are Associated With an Increased Risk of Band Keratopathy: A Population-Based Study in Taiwan.

Authors:  Ren-Long Jan; Jhi-Joung Wang; Sung-Huei Tseng; Yuh-Shin Chang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-15       Impact factor: 6.055

3.  Risk of Band Keratopathy in Patients with End-Stage Renal Disease.

Authors:  Shih-Feng Weng; Ren-Long Jan; Chun Chang; Jhi-Joung Wang; Shih-Bin Su; Chien-Cheng Huang; Sung-Huei Tseng; Yuh-Shin Chang
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.